糖尿病性腎症に対する脂質低下剤プロブコールの投与効果

概要

論文の詳細を見る
A year-long prospective study was conducted to elucidate the effects of probucol, an anti-oxidative hypolipidemic agent, on the progression of diabetic nephropathy. A total of 152 diabetic outpatients with an urinary albumin level of 200mg/g・Cr or more, and who routinely visited our hospital were divided into two groups of 75 patients treated with probucol (500mg/day) and 77 non-treated patients. All patients were observed for 12 months. The results reveled no significant difference in the blood pressure or HbA_1c level between the two groups. However, the serum lipid levels in the probucoltreated group decreased by 16 to 18%(p<0.01) for total cholesterol, 19 to 28% for neutral fat, and 17 to 21% (p<0.01) for HDL-cholesterol, while they did not significantly change in the non-treated group. As for the renal function, probucol suppressed the progression of nephropathy in a patients group with a moderate to severe serum creatinine and urinary albumin level and another patient group with a mild to moderate urinary protein level at severity level of from ± to 2+. Kidney dialysis was required in 2 probucol-treated patients and 9 nontreated patients, where the rate of dialysis shift after the serum creatinine concentration exceeded 2.0mg/dL was 15% in the probucol-treated group and 58% in the non-treated group. From the present results, it was suggested that probucol suppresses the progression of diabetic nephropathy, thereby extending the period until dialysis is required.
日本医療薬学会の論文
2002-10-10

糖尿病性腎症に対する脂質低下剤プロブコールの投与効果

スポンサーリンク

概要

著者

関連論文

スポンサーリンク